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Post-pulmonary tuberculosis 
complications in South Africa and 
a potential link with pulmonary 
hypertension: Premise for clinical and 
scientific investigations
To the Editor: The magnitude of the pulmonary tuberculosis (TB) 
epidemic in South Africa (SA) and globally[1] has received increased 
attention. Efforts have been made to explore new and improved 
diagnostic[2] and treatment strategies,[3] but the story does not end 
with treatment, and TB frequently results in long-term lung damage. 
This may include chronic airflow obstruction, reduced lung function 
(forced vital capacity) and destruction of the pulmonary vascular bed 
in cases of advanced lung disease.[4,5] This destruction of the vascular 
bed is attributed to parenchymal abnormalities that lead to reduced 
cross-sectional area of the pulmonary vasculature.[6]
We highlight the fact that long-term consequences of advanced 
destruction of the pulmonary vasculature may occur in the absence 
of significant parenchymal damage, and that this is another post-TB 
complication that remains largely unexplored. Few previous reports[7-9] 
and our clinical experience suggest that there is an association 
between post-TB lung disease and pulmonary hypertension (PHT). 
Although a proportion of patients with current TB do present 
with PHT,[7,8,10] the strength of this association remains largely 
undefined. [9,10] In addition, the prevalence of PHT among individuals 
who have been treated for pulmonary TB but who have minimal 
fibrotic parenchymal disease is also not known. We have noticed 
a paucity of literature listing TB as a potential cause of pulmonary 
vascular disease, or demonstrating an association between TB and 
PHT. Furthermore, the literature and PHT guideline documents 
rarely mention TB among the list of causes of group 3 PHT.[11]
We therefore propose that a discordance may exist between our 
clinical reality and the literature on post-TB pulmonary vascular 
disease and PHT. This discordance is difficult to explain, and may in 
part be due to a low TB incidence in countries currently researching 
PHT. It is possible that in their setting they do not frequently observe 
patients with TB progressing to advanced lung destruction, like we do 
here in SA. This highlights many important unanswered questions, that 
include: What is the strength of the association between pulmonary 
TB and PHT, across the spectrum of parenchymal abnormality in 
TB patients? Why does the degree of right heart failure correlate so 
poorly with the degree of radiological changes?[8] Does the degree of 
right heart failure correlate with the degree of airway obstruction/
restriction regardless of the degree of radiological changes? What is 
the time of onset of PHT in patients who were successfully treated 
for TB? Lastly, do other co-factors, such as smoking, drug use or HIV, 
have a modifying role in the development of PHT?
Considering that in SA there were an estimated 438 000 cases 
of tuberculosis in 2016 alone,[1] we highlight that further clinical 
investigation and research into this disease association is important. 
This research is essential if we are to design treatment strategies 
for these patients. Without sufficient data, management decisions 
appear to be largely informed by anecdotes. Moreover, management 
algorithms are usually extrapolated from those of other group 3 
PHT-related diseases (e.g. chronic obstructive pulmonary disease and 
pulmonary fibrosis),[11] where the mechanism of pathology is likely 
to be entirely different. In our clinical experience, it is clear that TB 
does not end with cessation of treatment, and long after the current 
epidemic is over we may be left with a generation of individuals still 
suffering long-term consequences, one of which is PHT.
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